Background: Despite biochemical euthyroidism, some levothyroxine (L-T4)-treated hypothyroid patients report persisting symptoms and some of these patients are tentatively treated with a combination of L-T4 and liothyronine (L-T3). Combination therapy and the appropriate choice of blood tests to monitor treatment are highly debated among specialists and patients. Aim: To evaluate whether measuring serum triiodothyronine (S-T3) at baseline or during combination therapy can be used as an indicator of a positive effect from L-T4/L-T3 combination therapy. Materials and Methods: Observational retrospective study of patients (n = 42) with persisting symptoms of hypothyroidism despite L-T4 therapy who had normal TSH levels and did not have any comorbidities that could explain their symptoms. All were then treated with L-T4/L-T3 combination therapy at a dose ratio of 17/1 according to European Thyroid Association guidelines. Based on patient-reported outcome, they were divided into responders and nonresponders. Results: Five patients were lost to follow-up and thus excluded. At the 3-month follow-up, 11 were classified as nonresponders and 26 as responders. At 12 months these figures had changed to 13 (35%) and 24 (65%), respectively. When comparing responders versus nonresponders, no differences were seen at baseline or during follow-up in S-T3 and in free T3 estimates. Further, logistic regression showed no correlation between S-T3 and free T3 estimates and responder/nonresponder status. Conclusion: Our data indicate that serum T3 measurements are not suitable to predict which patient will benefit from L-T4/L-T3 combination therapy, and treatment response cannot be followed by repeated T3 measurements either.
Eur Thyroid J
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jLEYUQ
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Background Liver resection of benign, primary, and metastatic tumors is challenging and places patients at risk of postoperativ...
-
Publication date: Available online 8 April 2017 Source: Cortex Author(s): Jeremy Purcell, Rajani Sebastian, Richard Leigh, Samson Jarso,...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2p4oxom via IFTTT
-
With a highly professional, friendly and compassionate staff, Coral Springs Funeral Home is the first choice for hundreds of area families e...
-
OBJECTIVE: This study was aimed to explore the underlying genes associated with lung cancer (LC) by bioinformatics analysis. DATA AND METH...
-
La Traviata The soprano Diana Damrau gave her first performance as Violetta in Verdi’s “Traviata” as it returned to the Metropolitan Opera. ...
-
Though TRAIL has been hailed as a promising drug for tumour treatment, it has been observed that many tumour cells have developed escape mec...
-
Sheffield cancer patient becomes 1000th person to have surgery using 'high-tech robot' South Yorkshire Times As well as prost...
-
Biomarkers for Hearing Dysfunction: Facts and Outlook. ORL J Otorhinolaryngol Relat Spec. 2017 Feb 24;79(1-2):93-111 Authors: Rüttige...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου